Business
Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2020
Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2020.
About this update from Avivagen, Inc.
[{"type":"text","content":"Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, announces its unaudited financial results for the second quarter of 2020.For the three-month period ended April 30, 2020, the Corporation reported revenues of $29,625, a decrease of $274,359 over the three-month period ended April 30, 2019. For the six-month period ended April 30, 2020, the Corporation reported revenues of $277,430, a decrease of $348,679 over the six-month period ended April 30, 2019.The comprehensive loss from continuing operations for the three-month period ended April 30, 2020 was $1,393,497 and for the six-month period ended April 30, 2020 was $2,725,277. As at April 30, 2020, the Corporation reported total assets of $2,671,014, total liabilities of $5,628,467 and shareholders’ equity (deficiency) of ($2,957,453). About AvivagenAvivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture and OTCQB® Venture Market exchanges under the symbols VIV and VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release. About OxC-beta™ Technology and OxC-beta™ LivestockAvivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia.Avivagen’s OxC-beta™ Livestock p...